期刊文献+

关于细胞制剂产品质量研究与质量控制的一些思考 被引量:5

Some considerations on quality research and quality control of cell preparation products
下载PDF
导出
摘要 近年来,细胞治疗成为研究热点,为肿瘤等重大和难治性疾病提供了新的治疗手段。本文针对细胞制剂产品的特点,提出细胞制剂产品质量研究和质量控制的一些思路和原则,包括生产质量管理规范、细胞制剂产品生产用原材料、制备工艺与过程控制、质量研究和质量控制等,希望通过不断完善的质量管理推进细胞制剂产品研发的健康发展。 Recently, cytotherapy has become a research hotpoint, which provide a novel therapeutic approach for tumor and other major and refractory disease. In this paper, some ideals and principles on quality research and quality control of the cell preparation products were suggested, including Good Manufacturing Practice (GMP), raw materials for production of the cell preparation, processing technique and process control, quality research and quality control, and so on. It hopes that successful research and development of the cell preparation products were advanced through continuous improvement of quality management.
作者 韦薇 常卫红 WEI Wei CHANG Weihong(Center for Drug Evaluation, China Food and Drug Administration, Beijing 100038, China China Food and Drug Administration, Beijing 100053,China)
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2016年第5期609-612,共4页 Chinese Journal of Cancer Biotherapy
关键词 细胞制剂 质量研究 质量控制 指导原则 cell preparation products quality research quality control guiding principles
  • 相关文献

参考文献8

  • 1JOAQUIM V,GLORIA C.2015.Guide to cell therapy gxp quality standards in the development of cell-based medicines in non-pharmaceutical environments.New York:Academic Press,2015.
  • 2F DA.Guidance for human somatic cell therapy and gene therapy[J].Hum Gene Ther,1998,9(10):1513-1524.
  • 3韩倩倩,王春仁.基因治疗产品、细胞治疗产品和组织工程产品在欧盟的监管[J].组织工程与重建外科杂志,2014,10(5):244-246. 被引量:6
  • 4黄清华.解密欧盟细胞疗法之监管体系[J].中国医院院长,2014,10(19):74-76. 被引量:1
  • 5FDA.Guidance for FDA reviewers and sponsors:content and review of chemistry,manufacturing and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs) [EB/OL].(2008-04-20) [2016-08-20].http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm074131.htm.
  • 6SFDA.人体细胞治疗研究和制剂质量控制技术指导原则[EB/OL].(2003-03-20)[2016-08-20].http://www.sda.gov.cn/WS01/CL0237/15709.html.
  • 7F DA,H HS.Revisions to exceptions applicable to certain human cells,tissues,and cellular and tissue-based products[J].Fed Regist,2016,81(120):40512-40518.
  • 8EMA.Guideline on human cell-based medicinal products [EB/OL].(2008-05-21)[2016-08-20].http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500003894&mid=WC0b01ac 058009a3dc.

共引文献5

同被引文献39

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部